Exelixis, Inc. Grows Revenue, Eyes Treating More Patients

Exelixis, Inc. Grows Revenue, Eyes Treating More Patients

Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.

Metric

Q2 2017

Continue reading

Source: Fool.com